Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04818346 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Vitiligo
A Phase 2 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 171
- Enrollment target
NCT04818346 is a Phase 2 study that has completed, run by Incyte Corporation. The registered enrollment target is 171 participants.
The verdict
NCT04818346, a Phase 2 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 171 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of INCB054707 over a 24-week placebo-controlled double-blind treatment period, followed by a 28-week double-blind extension period in participants with nonsegmental vitiligo.
Interventions
- DRUG Placebo
- DRUG INCB054707
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 171 participants |
| Start Date | 2021-05-06 |
| Est. Completion | 2023-05-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04818346
The ClinicalTrials.gov registry entry for NCT04818346 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 171 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04818346 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04818346 about?
NCT04818346 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Vitiligo". The purpose of this study is to evaluate the efficacy and safety of INCB054707 over a 24-week placebo-controlled double-blind treatment period, followed by a 28-week double-blind extension period in participants with nonsegmental vitiligo.
What is the current status of trial NCT04818346?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 171 participants. The study started on 2021-05-06. Estimated completion is 2023-05-24.
What interventions are being tested in trial NCT04818346?
The interventions under investigation include: Placebo (DRUG), INCB054707 (DRUG).
Who is sponsoring clinical trial NCT04818346?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.